Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03304418 · ClinicalTrials.gov registry record · Phase 2
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
A Phase 2 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03304418 is a Phase 2 study that has completed, run by University of Utah. The registered enrollment target is 20 participants.
The verdict
NCT03304418, a Phase 2 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a phase IIa, open label, single arm, and prospective study of hormone therapy-naïve men with oligometastatic prostate cancer to the bone. The study will test if treating the primary tumor sites and 5 or fewer sites of bone-only metastasis with external beam radiation with concomitant systemic Radium-223 will reduce the utilization of androgen deprivation therapy, improve QOL and improve OS over a the comparator cohort of SWOG intermittent ADT historic cohort.
Interventions
- RADIATION Radiation
- DRUG Radium Ra 223 Dichloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03304418
The ClinicalTrials.gov registry entry for NCT03304418 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiation is the first listed.
NCT03304418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03304418 about?
NCT03304418 is a clinical study titled "Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone". This is a phase IIa, open label, single arm, and prospective study of hormone therapy-naïve men with oligometastatic prostate cancer to the bone. The study will test if treating the primary tumor sites and 5 or fewer sites of bone-only metastasis with external beam radiation with concomitant systemi...
What is the current status of trial NCT03304418?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-02-27. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT03304418?
The interventions under investigation include: Radiation (RADIATION), Radium Ra 223 Dichloride (DRUG).
Who is sponsoring clinical trial NCT03304418?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.